STAG2 and acute myeloid leukemia: Given the near-mutual exclusivity of STAG2 and TP53 mutations in AML, we performed a subset analysis of cohesin-WT AML excluding TP53-mutant cases which removed most of the differences and showed a very similar and numerically even favorable outcome between STAG2-mutant and AML-MR without TP53 mutations.